Tempus AI, Inc.

TEM · Nasdaq · ·

对比

US$79.41-1.4%11月11日收盘

数据截至2026年9月30日，来自2026年11月2日提交的10-Q

1W: +4.4%
1M: +16.4%
3M: +46.3%

Tempus AI, Inc.（TEM）股票——这是一门好生意吗？ — InspectStocks

Tempus AI, Inc.

TEM · Nasdaq · ·

对比

US$79.41-1.4%11月11日收盘

数据截至2026年9月30日，来自2026年11月2日提交的10-Q

1W: +4.4%
1M: +16.4%
3M: +46.3%

Just reported

Q3 2026 results

From Tempus AI's results release of 2026年11月2日; its quarterly report has since been filed.

Revenue
Actual
US$411.5M
+23% y/y
+7.6% q/q
Guided
—
No guide given
EPS, GAAP
Actual
-US$0.08
Guided
—
No guide given
Operating income, GAAP
Actual
-US$56.9M
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$1.6B – US$1.605B+26% y/y Unchanged

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Tempus AI is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Health Information Services

Graded A or B and worth $2B or more: A first, then the largest.

All 41 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

怎么赚钱

Diagnostic testing75%
Data and applications25%

各项收入占比是对nine months ended September 30, 2026的估算，并非来自已提交报告的数字。

竞争对手

卖什么6

Tempus|xT
A test of cancer tissue that looks for gene changes that may help doctors understand a cancer and choose treatment.
Tempus|xF
A blood test that looks for cancer-related genetic material circulating in the blood.
Tempus|xG
Tests that look for inherited gene changes linked to cancer risk and other inherited conditions.

再显示 3 项

Insights
De-identified patient records and research tools that drug and biotechnology companies use to study diseases and develop medicines.
TIME Trial program
A service that helps doctors and drug companies find patients who may qualify for clinical trials.
Next
Software that checks patient information to help care teams spot missed tests or follow-up needs in cancer and heart care.

谁在买4

Doctors, genetic counselors, and hospitals order tests for patients; insurers, government health programs, patients, or the ordering institution may pay.
Pharmaceutical and biotechnology companies buy de-identified patient data, research tools, and analysis services.
Drug companies pay for help identifying patients who may qualify for clinical trials.
Academic research institutions buy laboratory testing and related research services.

靠什么支撑，什么会击垮它

业务依赖什么

1Its data business depends on continued access to patient records and permission to use and commercialize de-identified data.
2Clinical testing revenue depends in part on insurers and government health programs covering tests and paying enough to cover their cost.
3Laboratory testing relies on specialized instruments and materials from a limited number of suppliers, including some sole suppliers.
4The business depends on hospitals and other healthcare providers sharing data and using Tempus tests and software.

可能出什么问题

1If Tempus loses access to patient data or cannot continue to use and license it, its research data and related services could be affected.
2Insurers or government health programs may decline to cover tests, reduce payment, or change reimbursement rules, affecting the amount Tempus collects for diagnostic work.
3Changes to rules for laboratory tests and AI-based medical tools could require additional approvals or oversight, delay products, or limit how Tempus can sell them.

完整财务报表 →

关于Tempus AI, Inc.

Tempus runs laboratory tests that examine a patient’s cancer or inherited health risks, then connects results with medical records and other patient information. It uses artificial intelligence (AI) to help doctors interpret results and identify possible treatments or clinical trials. Drug and biotechnology companies pay Tempus for de-identified patient data, research tools, and help finding patients for trials.

总部: Chicago, Illinois
成立于: 2015
上市于: Nasdaq
财年结束: December 31

基于 Tempus AI, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。

Just reported